Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate MannKind Corporation before investing.

In this article, we go over a few key elements for understanding MannKind Corporation’s stock price such as:

• MannKind Corporation’s current stock price and volume
• Why MannKind Corporation’s stock price changed recently
• Upgrades and downgrades for MNKD from analysts
• MNKD’s stock price momentum as measured by its relative strength

About MannKind Corporation (MNKD)

Before we jump into MannKind Corporation’s stock price, history, target price and what caused it to recently dip, let’s take a look at some background.

MannKind Corporation, a biopharmaceutical company, focuses on the provision of various solutions for transforming chronic disease care. It develops and commercializes treatments that address serious unmet medical needs, including diabetes, pulmonary hypertension, and fluid overload in heart failure and chronic kidney disease. It offers Afrezza inhalation powder, an inhaled insulin used to improve glycemic control in adults with diabetes; and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults. Its products also include Tyvaso DPI for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease; FUROSCIX, a furosemide injection to treat fluid buildup in patients with chronic heart failure or chronic kidney disease. The company’s pipeline of treatments for orphan lung diseases include MNKD-201, a dry-powder formulation of nintedanib for the treatment of idiopathic pulmonary fibrosis and MNKD-701. It has collaboration and license agreement with United Therapeutics Corporation for development, regulatory, and commercial activities of Tyvaso DPI; and collaboration agreement with Thirona to evaluate the therapeutic for the treatment of pulmonary fibrosis. MannKind Corporation was incorporated in 1991 and is headquartered in Danbury, Connecticut.

Want to learn more about MannKind Corporation’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about MannKind Corporation.

MannKind Corporation’s Stock Price as of Market Close

As of August 21, 2026, 4:00 PM, CST, MannKind Corporation’s stock price was $4.150.

MannKind Corporation is down 2.58% from its previous closing price of $4.260.

During the last market session, MannKind Corporation’s stock traded between $4.110 and $4.360. Currently, there are approximately 309.19 million shares outstanding for MannKind Corporation.

MannKind Corporation’s trailing earnings per share are negative, so the stock does not have a meaningful P/E ratio. We suggest investors evaluate other financial metrics to understand its overall valuation.

MannKind Corporation Stock Price History

MannKind Corporation’s (MNKD) price is currently up 6.14% so far this month.

During the month of August, MannKind Corporation’s stock price has reached a high of $4.400 and a low of $3.630.

Over the last year, MannKind Corporation has hit prices as high as $6.510 and as low as $2.230. Year to date, MannKind Corporation’s stock is down 26.81%.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused MannKind Corporation Stock’s Price to Dip?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of August 21, 2026, there were 2 analysts who downgraded MannKind Corporation’s stock and 1 analyst who upgraded over the last month.

Additionally, you'll want to evaluate MannKind Corporation’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on MannKind Corporation’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

MannKind Corporation’s current valuation based on AAII’s Value Grade is a F, which means it is considered to be Ultra Expensive.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about MannKind Corporation (MNKD) by visiting AAII Stock Evaluator.

Relative Price Strength of MannKind Corporation

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of August 21, 2026, MannKind Corporation has a weighted four-quarter relative price strength of 4.92%, which translates to a Momentum Score of 68 and is considered to be Strong.

Want to learn more about how MannKind Corporation is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

MannKind Corporation Stock Price: Bottom Line

As of August 21, 2026, MannKind Corporation’s stock price is $4.150, which is down 2.58% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like MannKind Corporation stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.